Amazon Pharmacy (AMZN) and Rite Aid (RAD) can’t get enough supply of Eli Lilly’s weight loss drug Zepbound as patient, pharmacist and doctor complaints mount, Bloomberg’s Ike Swetlitz and Madison Muller report. While Eli Lilly says the drug is available for pharmacies across the U.S. to order from their wholesaler, multiple pharmacists across the U.S. told Bloomberg earlier this week that some or all of the doses of the drug were on back-order amid soaring demand since the shot’s launch in December.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Viking (NASDAQ:VKTX): Positive Trial Data Boosts Stock
- Amgen shares worth $240-$250 without obesity pipeline, says JPMorgan
- Argus cuts Pfizer to Hold on headwinds to revenue growth
- Redwire: Lilly investigation yields ‘exciting’ results for drug discovery
- Medicare Part D may cover Novo obesity drug, WSJ reports